Baidu
map

药械

订阅

MedSci主页 / 所有栏目 / 药械

CD37：艾伯维/Genmab合作的重要靶点

2020-10-11 Eastwood 生物制药小编

靶点药物靶点CD37
关注

2020年6月，艾伯维与Genmab达成40亿美元合作协议（预付款7.5亿美元），共同开发后者的CD3/CD20双抗、CD37双表位双抗和CD3/5T4双抗。

2020年6月，艾伯维与Genmab达成40亿美元合作协议（预付款7.5亿美元），共同开发后者的CD3/CD20双抗、CD37双表位双抗和CD3/5T4双抗。

Genmab的CD37双表位双抗建立在其DuoHexabody技术上，引入E430G突变起到抗原结合依赖的六聚体形成，引入F405L、K409R体外构建双特异性抗体。六聚体的主要作用是增强补体CDC活性。

CD37双抗基于010和016两个单抗构建，其结合表位如下图。

In vitro和ex vivo试验表明，DuoHexaBody-CD37诱导更强的补体CDC活性。

DuoHexaBody-CD37特异性清除B细胞，对其他淋巴细胞则没有影响。

小鼠肿瘤模型中，DuoHexaBody-CD37表现出更强的抗肿瘤活性。

小编总结
CD37在多种B细胞淋巴瘤上广泛表达，包括NHL和CLL等。DuoHexaBody-CD37整合的Duobody和Hexabody两种技术，同时靶向CD37的两个表位，且能诱导极强的CDC效应。国外目前有多个CD37抗体或ADC处于临床前或早期临床阶段。国内该靶点尚少有企业布局，目前仅CDMO企业皓阳生物申报了一款CD19/CD37双抗专利。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1912455, encodeId=8fb119124551f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Feb 15 14:36:35 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350231, encodeId=da32135023144, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86746, encryptionId=bc1086e4652, topicName=艾伯维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Oct 13 04:36:35 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561976, encodeId=934515619e62c, content=<a href='/topic/show?id=ecc2431e6a' target=_blank style='color:#2F92EE;'>#CD37#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4317, encryptionId=ecc2431e6a, topicName=CD37)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Oct 13 04:36:35 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891385, encodeId=34ff89138511, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4325398811, createdName=ms4000002070088423, createdTime=Mon Oct 12 08:04:53 CST 2020, time=2020-10-12, status=1, ipAttribution=)]
    2021-02-15 snf701207

    #mAb#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1912455, encodeId=8fb119124551f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Feb 15 14:36:35 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350231, encodeId=da32135023144, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86746, encryptionId=bc1086e4652, topicName=艾伯维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Oct 13 04:36:35 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561976, encodeId=934515619e62c, content=<a href='/topic/show?id=ecc2431e6a' target=_blank style='color:#2F92EE;'>#CD37#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4317, encryptionId=ecc2431e6a, topicName=CD37)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Oct 13 04:36:35 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891385, encodeId=34ff89138511, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4325398811, createdName=ms4000002070088423, createdTime=Mon Oct 12 08:04:53 CST 2020, time=2020-10-12, status=1, ipAttribution=)]
    2020-10-13 zhaojie88

    #艾伯维#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1912455, encodeId=8fb119124551f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Feb 15 14:36:35 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350231, encodeId=da32135023144, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86746, encryptionId=bc1086e4652, topicName=艾伯维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Oct 13 04:36:35 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561976, encodeId=934515619e62c, content=<a href='/topic/show?id=ecc2431e6a' target=_blank style='color:#2F92EE;'>#CD37#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4317, encryptionId=ecc2431e6a, topicName=CD37)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Oct 13 04:36:35 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891385, encodeId=34ff89138511, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4325398811, createdName=ms4000002070088423, createdTime=Mon Oct 12 08:04:53 CST 2020, time=2020-10-12, status=1, ipAttribution=)]
    2020-10-13 docwu2019

    #CD37#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1912455, encodeId=8fb119124551f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Feb 15 14:36:35 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350231, encodeId=da32135023144, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86746, encryptionId=bc1086e4652, topicName=艾伯维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Oct 13 04:36:35 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561976, encodeId=934515619e62c, content=<a href='/topic/show?id=ecc2431e6a' target=_blank style='color:#2F92EE;'>#CD37#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4317, encryptionId=ecc2431e6a, topicName=CD37)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Oct 13 04:36:35 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891385, encodeId=34ff89138511, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4325398811, createdName=ms4000002070088423, createdTime=Mon Oct 12 08:04:53 CST 2020, time=2020-10-12, status=1, ipAttribution=)]
    2020-10-12 ms4000002070088423

    厉害

    0

相关资讯

Nat neuroscience:AHR是寨卡病毒的宿主因子并且是抗病毒治疗的候选靶点

寨卡病毒(Zika Virus，ZIKV)是一种与包括小头畸形在内的多个出生缺陷相关的黄病毒，被称为先天性ZIKV综合征。

Sci transl med：DHODH，可作为治疗小细胞肺癌的特异性靶点

小细胞肺癌（SCLC）是一种侵袭性的癌症亚型，预后极差。目前尚无可作靶点的遗传驱动事件，该疾病的治疗方案已经超过30年几乎没有改变过了。近期，研究人员通过以CRISPR为基础的筛选方法在SCLC中鉴别可作为潜在治疗靶点的遗传缺陷。研究人员采用单导向RNA（sgRNA）文库，针对被认为编码“可用药”蛋白的约5000个基因，在SCLC、肺腺癌(LUAD)和胰腺导管腺癌(PDAC)的自体基因工程小鼠模型

PNAS：强强联手！新组合用药有望“创造”靶点，实现对癌症“围追堵截”

随着社会科技的发展，癌症治疗观念正在发生根本性的改变。其中通过设计合适的治疗药物，使其根据肿瘤细胞上的分子靶点对肿瘤细胞进行精准打击的“生物导弹”——靶向治疗俨然成为了肿瘤研究的热点。但是这种治疗方式的适应症有限，仅针对具有特殊靶点的癌症，使得靶点问题成了阻碍其广泛应用的一大难题。

Sci Transl Med：很多抗癌药从一开始就搞错了！冷泉港科学家研究10种在研药发现，它们的作用靶点根本就不是科学家预设的那个

随着科学的发展，人们对疾病的发病机制的认识也越来越精准，哪个基因哪个蛋白出了毛病都能搞得清清楚楚。相应的，对药物的研发也从神农尝百草式的撞大运，变成了针对靶点的药物筛选，比如大名鼎鼎的格列卫，就是根据费城染色体的融合基因开发的。

J Allergy Clin Immun：鼻炎有救了！研究发现慢性鼻窦炎的治疗靶点

大阪大学的研究人员近日研究了semaphorin蛋白的活性，这是一种细胞表面分子，参与了神经系统的信号传统和免疫分析。他们发现，semaphorin蛋白促进了ECRS患者的过敏反应和鼻息肉的发展。

Science：癌症免疫疗法新靶点——VISTA

虽然机体需要强大的免疫反应来对抗感染，但免疫系统也必须控制这种反应的强度，以免对健康组织造成伤害。在过去10年里，美国科学家Randolph Noelle博士团队已经发现了许多被免疫系统用来“缓和”免疫反应的分子。不过，尽管这些被称为“负性检查点调节因子”的分子通常是有益的，能够通过调节T细胞对自身抗原的免疫反应来限制自身免疫的发展，但它们也会像“刹车”一样限制免疫系统对癌细胞的攻击。VIST

Baidu
map
Baidu
map
Baidu
map